HS-10296 is primarily utilized in the field of oncology as a targeted therapy for non-small cell lung cancer (NSCLC). It functions as an inhibitor of the epidermal growth factor receptor (EGFR), specifically targeting mutations like T790M, which are often associated with resistance to first-generation EGFR inhibitors. By blocking these mutated receptors, it helps to slow down or stop the growth of cancer cells, offering a treatment option for patients who have developed resistance to other EGFR-targeted therapies. Its application is particularly significant in cases where traditional treatments have failed, providing a potential pathway for improved patient outcomes.